The FDA has classified a recall of more than 2.5 million bottles of prescription prednisolone acetate eye drops as Class II after the product was found to contain a foreign substance.
The recall affects 2,530,182 bottles of Prednisolone Acetate Ophthalmic Suspension, USP, 1% in 5 milliliter, 10 milliliter and 15 milliliter presentations manufactured by Lupin Limited and distributed nationwide, according to a June 30 enforcement report.
The voluntary recall was initiated June 4 and classified by the FDA on June 30. It remains ongoing. The affected products include multiple lots with expiration dates ranging from July through October 2026.
The recall follows a similar one in March, when K.C. Pharmaceuticals recalled more than 3.1 million bottles of over-the-counter eye drops, including store-brand products sold at CVS Health, Walgreens, Kroger and Cardinal Health, after the company could not verify the sterility of the products.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.